PMC:7195088 / 9641-9918 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"169","span":{"begin":236,"end":244},"obj":"Species"},{"id":"202","span":{"begin":105,"end":112},"obj":"Chemical"},{"id":"203","span":{"begin":182,"end":189},"obj":"Chemical"},{"id":"240","span":{"begin":208,"end":226},"obj":"Disease"},{"id":"241","span":{"begin":227,"end":235},"obj":"Disease"}],"attributes":[{"id":"A169","pred":"tao:has_database_id","subj":"169","obj":"Tax:9606"},{"id":"A202","pred":"tao:has_database_id","subj":"202","obj":"MESH:D013256"},{"id":"A203","pred":"tao:has_database_id","subj":"203","obj":"MESH:D013256"},{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"MESH:D016638"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" admission). Yet in the absence of convincing evidence, the following cannot currently be supported: (1) steroid administration stratified according to inflammatory markers; and (b) steroid administration in non–critically ill COVID-19 patients.\nQuestion 6. Should other immuno"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T50","span":{"begin":227,"end":235},"obj":"Disease"}],"attributes":[{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" admission). Yet in the absence of convincing evidence, the following cannot currently be supported: (1) steroid administration stratified according to inflammatory markers; and (b) steroid administration in non–critically ill COVID-19 patients.\nQuestion 6. Should other immuno"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T31","span":{"begin":179,"end":180},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":" admission). Yet in the absence of convincing evidence, the following cannot currently be supported: (1) steroid administration stratified according to inflammatory markers; and (b) steroid administration in non–critically ill COVID-19 patients.\nQuestion 6. Should other immuno"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T42","span":{"begin":105,"end":112},"obj":"Chemical"},{"id":"T43","span":{"begin":182,"end":189},"obj":"Chemical"}],"attributes":[{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_35341"}],"text":" admission). Yet in the absence of convincing evidence, the following cannot currently be supported: (1) steroid administration stratified according to inflammatory markers; and (b) steroid administration in non–critically ill COVID-19 patients.\nQuestion 6. Should other immuno"}

{"project":"LitCovid-sentences","denotations":[{"id":"T66","span":{"begin":13,"end":245},"obj":"Sentence"},{"id":"T67","span":{"begin":246,"end":257},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" admission). Yet in the absence of convincing evidence, the following cannot currently be supported: (1) steroid administration stratified according to inflammatory markers; and (b) steroid administration in non–critically ill COVID-19 patients.\nQuestion 6. Should other immuno"}